Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - Skye Bioscience (NASDAQ:SKYE)

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - Skye Bioscience (NASDAQ:SKYE) — alphai